Mobilization of refractory chronic schizophrenics with haloperidol

M. Psaras, N. P. Zissis, D. Mouzakis, Constantine G Lyketsos

Research output: Contribution to journalArticle

Abstract

Adequate high doses of haloperidol have been administered to 24 chronic, refractory to standard antipsychotic treatment, schizophrenics (16 male, 8 female, mean age 32.9 years) to investigate the possibility of mobilizing and releasing these patients from the hospital. Treatment was started with 20 mg haloperidol and optimal doses were determined for each patient. The median daily optimal dose at the end of the trial was 100 mg. All patients were followed up for 16 weeks. Evaluating criteria were the BPRS, the Discharge Readiness Questionnaire, a side-effect rating scale, a CGI scale and the number of patients able to leave the hospital. 3 patients were evaluated as able to leave the hospital. 87.4% of the patients were subjectively evaluated as improved. High doses of haloperidol did not correlate with a higher incidence of unwanted effects. On the contrary antiparkinson treatment was discontinued or decreased in 14 patients. It is concluded that nonresponsive chronic schizophrenics can profit from adequate high doses of haloperidol.

Original languageEnglish (US)
Pages (from-to)180-185
Number of pages6
JournalInternational Pharmacopsychiatry
Volume15
Issue number3
StatePublished - 1980
Externally publishedYes

Fingerprint

Haloperidol
Antipsychotic Agents
Therapeutics
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mobilization of refractory chronic schizophrenics with haloperidol. / Psaras, M.; Zissis, N. P.; Mouzakis, D.; Lyketsos, Constantine G.

In: International Pharmacopsychiatry, Vol. 15, No. 3, 1980, p. 180-185.

Research output: Contribution to journalArticle

Psaras, M. ; Zissis, N. P. ; Mouzakis, D. ; Lyketsos, Constantine G. / Mobilization of refractory chronic schizophrenics with haloperidol. In: International Pharmacopsychiatry. 1980 ; Vol. 15, No. 3. pp. 180-185.
@article{ba7e3ec66f914f98a58a8a13fc65e854,
title = "Mobilization of refractory chronic schizophrenics with haloperidol",
abstract = "Adequate high doses of haloperidol have been administered to 24 chronic, refractory to standard antipsychotic treatment, schizophrenics (16 male, 8 female, mean age 32.9 years) to investigate the possibility of mobilizing and releasing these patients from the hospital. Treatment was started with 20 mg haloperidol and optimal doses were determined for each patient. The median daily optimal dose at the end of the trial was 100 mg. All patients were followed up for 16 weeks. Evaluating criteria were the BPRS, the Discharge Readiness Questionnaire, a side-effect rating scale, a CGI scale and the number of patients able to leave the hospital. 3 patients were evaluated as able to leave the hospital. 87.4{\%} of the patients were subjectively evaluated as improved. High doses of haloperidol did not correlate with a higher incidence of unwanted effects. On the contrary antiparkinson treatment was discontinued or decreased in 14 patients. It is concluded that nonresponsive chronic schizophrenics can profit from adequate high doses of haloperidol.",
author = "M. Psaras and Zissis, {N. P.} and D. Mouzakis and Lyketsos, {Constantine G}",
year = "1980",
language = "English (US)",
volume = "15",
pages = "180--185",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Mobilization of refractory chronic schizophrenics with haloperidol

AU - Psaras, M.

AU - Zissis, N. P.

AU - Mouzakis, D.

AU - Lyketsos, Constantine G

PY - 1980

Y1 - 1980

N2 - Adequate high doses of haloperidol have been administered to 24 chronic, refractory to standard antipsychotic treatment, schizophrenics (16 male, 8 female, mean age 32.9 years) to investigate the possibility of mobilizing and releasing these patients from the hospital. Treatment was started with 20 mg haloperidol and optimal doses were determined for each patient. The median daily optimal dose at the end of the trial was 100 mg. All patients were followed up for 16 weeks. Evaluating criteria were the BPRS, the Discharge Readiness Questionnaire, a side-effect rating scale, a CGI scale and the number of patients able to leave the hospital. 3 patients were evaluated as able to leave the hospital. 87.4% of the patients were subjectively evaluated as improved. High doses of haloperidol did not correlate with a higher incidence of unwanted effects. On the contrary antiparkinson treatment was discontinued or decreased in 14 patients. It is concluded that nonresponsive chronic schizophrenics can profit from adequate high doses of haloperidol.

AB - Adequate high doses of haloperidol have been administered to 24 chronic, refractory to standard antipsychotic treatment, schizophrenics (16 male, 8 female, mean age 32.9 years) to investigate the possibility of mobilizing and releasing these patients from the hospital. Treatment was started with 20 mg haloperidol and optimal doses were determined for each patient. The median daily optimal dose at the end of the trial was 100 mg. All patients were followed up for 16 weeks. Evaluating criteria were the BPRS, the Discharge Readiness Questionnaire, a side-effect rating scale, a CGI scale and the number of patients able to leave the hospital. 3 patients were evaluated as able to leave the hospital. 87.4% of the patients were subjectively evaluated as improved. High doses of haloperidol did not correlate with a higher incidence of unwanted effects. On the contrary antiparkinson treatment was discontinued or decreased in 14 patients. It is concluded that nonresponsive chronic schizophrenics can profit from adequate high doses of haloperidol.

UR - http://www.scopus.com/inward/record.url?scp=0019291160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019291160&partnerID=8YFLogxK

M3 - Article

C2 - 7239842

AN - SCOPUS:0019291160

VL - 15

SP - 180

EP - 185

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 3

ER -